Spark Therapeutics, Inc.

ACTIVE

3737 Market St Ste 1300, 宾夕法尼亚州费拉德尔菲亚县, Pennsylvania, United Stateswww.sparktx.comPublic501–1,000 employeesEstablished: 2013-01-01

Part of Roche Holdings, Inc.

Clinical Trials

5 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2013

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

53.3%

Phase 3

13.3%

Not Applicable

6.7%

Trial Status Distribution

Active, not recruiting

33.3%

Completed

53.3%

Terminated

6.7%

Withdrawn

6.7%

Clinical Trials

Trials sponsored by this organization (15)

Study of a Gene Therapy Treatment for Hemophilia A

Phase 3

Withdrawn

interventional

Mar 202485 participants

A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)

Phase 1

Active, not recruiting

interventional

Oct 20204 participants

Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease

Not Applicable

Completed

interventional

Jun 201961 participants

Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

Phase 1

Completed

interventional

Jan 20194 participants

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

Completed

observational

Jan 201925 participants

A Patient Registry Study for Patients Treated With Voretigene Neparvovec in US

Completed

observational

Jan 201987 participants

Long-Term Safety and Efficacy of Spark-Sponsored Gene Therapies in Males With Hemophilia A

Active, not recruiting

observational

Aug 201829 participants

A Gene Transfer Study for Hemophilia A

Phase 1

Completed

interventional

Jan 201725 participants

Page 1 of 2

Approvals

Approvals by Agency

FDA

Food and Drug Administration

Approvals

Recent Approvals

News

No news articles found

Back to Organizations